Optimal tumour targeting by antibodies: Kinetic consideration
UNSPECIFIED (1996) Optimal tumour targeting by antibodies: Kinetic consideration. ADVANCED DRUG DELIVERY REVIEWS, 19 (3). pp. 469-484. ISSN 0169-409XFull text not available from this repository.
Previously, a model has been developed and used to quantitate the antibody characteristics which influence the effectiveness of tumour radioimmunotherapy. Analysis has covered two different antibody molecules (the IgG molecule and a ligand, a theoretical fragment of the IgG molecule, approximating to a single binding site), three different tumour sizes (1 g, 10 g and 100 g), four different radiolabels (I-131, H-3, P-32 and Y-90) and a range of antibody dose sizes (from 0.1 to 1000 mg) and tissue affinities (from 10(9) to 10(13) mol(-1)). When dealing with protracted radiation doses, there is a significant effect from the gradual repair of partially damaged cells and this effect has also been implemented. The success of the treatment is measured by the therapeutic index (TI), with the model predicting higher TI for the ligand (if the affinity is large enough), the largest tumour, the H-3 radiolabel (although this is also shown to be impractical due to the low energy of its photons) and the higher affinities. It also predicts an optimal dose size although this differs for the two different antibody molecules.
|Item Type:||Journal Item|
|Subjects:||R Medicine > RS Pharmacy and materia medica|
|Journal or Publication Title:||ADVANCED DRUG DELIVERY REVIEWS|
|Publisher:||ELSEVIER SCIENCE BV|
|Date:||12 June 1996|
|Number of Pages:||16|
|Page Range:||pp. 469-484|
Actions (login required)